These results indicate that DCs play an important role in the immunotherapy circuits of TIGIT-inhibiting CD8 + T cell responses, and that the development of drugs targeting DCs can contribute to the improvement of anti-tumor efficacy. This evidence concerns the gene CD8A and neoplasm.